AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir.

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

PhRMA said in a January submission to the US trade review that US companies were the “constant target of compulsory licensing ...

Emphasis must be on balancing enforcement with innovation, protection with access, and litigation with alternative dispute resolution ...

Merging the Crown use and compulsory licensing regimes by introducing a single, streamlined framework for public interest access to patented technologies. Allow both government and private entities to ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Pharma industry bodies have slammed a proposal by the European Commission to set up a compulsory licensing (CL) framework for medicines in emergency situations, claiming there is no need for the move.

Lupin Ltd has partnered with Zentiva Group to commercialize its biosimilar 'Certolizumab Pegol' across global markets. The ...

Pharma is missing opportunities to maximise the benefits of applying a digital approach on a global scale, says Gregg Fisher. Managing for global impact continues to be a challenge for many pharma ...

Pharma major Lupin has signed a USD 50 million agreement with a European pharmaceutical company. Lupin has entered into a ...